{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:59:53Z","timestamp":1787068793864,"version":"build-2736575974"},"reference-count":109,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDD"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract:<\/jats:title>\n                    <jats:p>Oral squamous cell carcinoma is a malignant disease that is causing considerable mortality\nworldwide. Conventional treatment approaches, like surgery, cause destructive alterations in facial appearance\nand oral function impairments associated with psychological and social functioning. Chemotherapy\nexhibits low bioaccessibility of the anticancer drugs, multiple drug resistance, higher dose necessities,\nwhich elevate toxicities to the normal cells, low therapeutic index, and non-specific targeting.\nRadiation therapies significantly affect the well-being of the patient and impair the quality of life.\nTherefore, chemotherapeutics are developed that can either actively or passively target the carcinomas,\nreduce the adverse side effect, and improve therapeutic efficacy. Innovations in novel drug delivery\nsystems deliver the drugs to the desired site of action with better treatment approaches with reduced\ntoxicities to the normal cells and improve the health and survival rate of the patient. Cancer chronotherapy\nenhances the treatment proficiency by administration of the drugs at the best time, considering biological\ntimings to improve the treatment profiles. Chronotherapy provides benefits to the current anticancer\ntherapies, with minimum adverse effects to the healthy cells. This review discusses the risk factors\nfor oral carcinomas, targeted therapy by nanocarriers, nanotechnology approaches, the role of circadian\nrhythm in the management of oral cancer, and advances in controlled drug delivery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1567201819666220408094520","type":"journal-article","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T01:18:50Z","timestamp":1649639930000},"page":"237-249","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Current Novel Drug Deliveries for Oral Cancer: A Chronotherapeutic\nApproach"],"prefix":"10.2174","volume":"20","author":[{"given":"Kishori P.","family":"Sutar","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics, KLE College of Pharmacy, KLE Academy of Higher Education and Research, Nehru\nNagar, Belagavi 590010, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha S.","family":"Shirkoli","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Quality Assurance, KLE College of Pharmacy,\nKLE Academy of Higher Education and Research, Nehru Nagar, Belagavi 590010, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasanna S.","family":"Sutar","sequence":"additional","affiliation":[{"name":"Department of Pharmacognosy, Maratha Mandal\u2019s College of Pharmacy, M M Extension, Belagavi 590010, Karnataka,\nIndia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0080-0369","authenticated-orcid":true,"given":"Bhaskar K.","family":"Kurangi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, KLE College of Pharmacy, KLE Academy of Higher Education and Research, Nehru\nNagar, Belagavi 590010, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panchaxari M.","family":"Dandagi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, KLE College of Pharmacy, KLE Academy of Higher Education and Research, Nehru\nNagar, Belagavi 590010, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajashree","family":"Masareddy","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, KLE College of Pharmacy, KLE Academy of Higher Education and Research, Nehru\nNagar, Belagavi 590010, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41392-017-0004-3","volume":"3","author":"Senapati S.","year":"2018","unstructured":"Senapati S.; Mahanta A.K.; Kumar S.; Maiti P.; Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduct Target Ther 2018,3(7),7","journal-title":"Signal Transduct Target Ther"},{"key":"ref=2","first-page":"1328","volume":"6","author":"Masthan K.","year":"2012","unstructured":"Masthan K.; Babu N.A.; Shanmugam K.T.; Abhinav J.; Nanotechnology: Its application in oral cancer. JCDR 2012,6,1328-1330","journal-title":"JCDR"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2157-7439.1000103e","volume":"2","author":"Nguyen K.T.","year":"2011","unstructured":"Nguyen K.T.; Targeted nanoparticles for cancer therapy: Promises and challenges. J Nanomed Nanotechnol 2011,2(5),1-2","journal-title":"J Nanomed Nanotechnol"},{"key":"ref=4","first-page":"01","volume":"1","author":"Deepak K","year":"2011","unstructured":"Deepak K; Deepti J; Vivek S; Rajendra K; Patil, A cancer therapeutics, opportunities, challenges and advances in drug delivery. JAPS 2011,1,01-10","journal-title":"JAPS"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.15713\/ins.jmrps.15","volume":"1","author":"Rao R.S.","year":"2015","unstructured":"Rao R.S.; Patil S.; Ghosh S.; Kumari K.; Current aspects and future strategies in oral cancer research: A review. J Med Radiol Pathol Surg 2015,1,8-13","journal-title":"J Med Radiol Pathol Surg"},{"key":"ref=6","first-page":"62","volume":"11","author":"Virupakshappa B.","year":"2012","unstructured":"Virupakshappa B.; Applications of nanomedicine in oral cancer. Oral Health Dent Manag 2012,11(2),62-68","journal-title":"Oral Health Dent Manag"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1102\/1470-7330.2010.0008","volume":"10","author":"Tshering Vogel D.W.","year":"2010","unstructured":"Tshering Vogel D.W.; Zbaeren P.; Thoeny H.C.; Cancer of the oral cavity and oropharynx. Cancer Imaging 2010,10(62),62-72","journal-title":"Cancer Imaging"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-016-0512-8","volume":"15","author":"Manikandan M.","year":"2016","unstructured":"Manikandan M.; Deva Magendhra Rao A.K.; Arunkumar G.; Manickavasagam M.; Rajkumar K.S.; Rajaraman R.; Munirajan A.K.; Oral squamous cell carcinoma: microRNA expression profiling and integrative analyses for elucidation of tumourigenesis mechanism. Mol Cancer 2016,15(1),28","journal-title":"Mol Cancer"},{"key":"ref=9","first-page":"11884","volume":"8","author":"Rivera C.","year":"2015","unstructured":"Rivera C.; Essentials of oral cancer. Int J Clin Exp Pathol 2015,8(9),11884-11894","journal-title":"Int J Clin Exp Pathol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40496-016-0081-3","volume":"3","author":"Prince V.M.","year":"2016","unstructured":"Prince V.M.; Papagerakis S.; Prince M.E.; Oral cancer and cancer stem cells: Relevance to oral cancer risk factors, premalignant lesions, and treatment. Curr Oral Health Rep 2016,3(2),65-73","journal-title":"Curr Oral Health Rep"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/onc.2014.15","volume":"34","author":"Adams A.K.","year":"2015","unstructured":"Adams A.K.; Hallenbeck G.E.; Casper K.A.; Patil Y.J.; Wilson K.M.; DEK promotes HPV-positive and-negative head and neck cancer cell proliferation. Oncogene 2015,34,868","journal-title":"Oncogene"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1080\/21505594.2014.999570","volume":"6","author":"H&#xFC;bbers C.U.","year":"2015","unstructured":"H&#xFC;bbers C.U.; Akg&#xFC;l B.; HPV and cancer of the oral cavity. Virulence 2015,6(3),244-248","journal-title":"Virulence"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1601-0825.1995.tb00158.x","volume":"1","author":"Gupta P.C.","year":"1995","unstructured":"Gupta P.C.; Murti P.R.; Bhonsle R.B.; Mehta F.S.; Pindborg J.J.; Effect of cessation of tobacco use on the incidence of oral mucosal lesions in a 10-yr follow-up study of 12,212 users. Oral Dis 1995,1(1),54-58","journal-title":"Oral Dis"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/S1368-8375(99)00019-6","volume":"35","author":"Warnakulasuriya K.A.","year":"1999","unstructured":"Warnakulasuriya K.A.; Johnson N.W.; Linklater K.M.; Bell J.; Cancer of mouth, pharynx and nasopharynx in Asian and Chinese immigrants resident in Thames regions. Oral Oncol 1999,35(5),471-475","journal-title":"Oral Oncol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S1368-8375(00)00007-5","volume":"36","author":"Scully C.","year":"2000","unstructured":"Scully C.; Field J.K.; Tanzawa H.; Genetic aberrations in oral or head and neck squamous cell carcinoma (SCCHN): 1. Carcinogen metabolism, DNA repair and cell cycle control. Oral Oncol 2000,36(3),256-263","journal-title":"Oral Oncol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1600-0714.2007.00496.x","volume":"36","author":"Warnakulasuriya K.A.","year":"2007","unstructured":"Warnakulasuriya K.A.; Ralhan R.; Clinical, pathological, cellular and molecular lesions caused by oral smokeless tobacco-a review. J Oral Pathol Med 2007,36(2),63-77","journal-title":"J Oral Pathol Med"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nrc1190","volume":"3","author":"Hecht S.S.","year":"2003","unstructured":"Hecht S.S.; Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer 2003,3(10),733-744","journal-title":"Nat Rev Cancer"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.3892\/ijo.2014.2355","volume":"44","author":"Dalianis T.","year":"2014","unstructured":"Dalianis T.; Human papillomavirus and oropharyngeal cancer, the epidemics, and significance of additional clinical biomarkers for prediction of response to therapy (Review). Int J Oncol 2014,44(6),1799-1805","journal-title":"Int J Oncol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrclinonc.2014.192","volume":"12","author":"Kang H.","year":"2015","unstructured":"Kang H.; Kiess A.; Chung C.H.; Emerging biomarkers in head and neck cancer in the era of genomics. Nat Rev Clin Oncol 2015,12(1),11-26","journal-title":"Nat Rev Clin Oncol"},{"key":"ref=20","author":"Neville B.W.","year":"2009","unstructured":"Neville B.W.; Damm D.D.; Allen C.; Chi A.;  Oral and Maxillofacial Pathology 2009","journal-title":"Oral and Maxillofacial Pathology"},{"key":"ref=21","first-page":"9445","volume":"23","author":"Zhu Y.","year":"2019","unstructured":"Zhu Y.; Wen L.M.; Li R.; Dong W.; Jia S.Y.; Qi M.C.; Recent advances of nano-drug delivery system in oral squamous cell carcinoma treatment. Eur Rev Med Pharmacol Sci 2019,23(21),9445-9453","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1021\/bc400271x","volume":"25","author":"Afifi M.M.","year":"2014","unstructured":"Afifi M.M.; Austin L.A.; Mackey M.A.; El-Sayed M.A.; XAV939: From a small inhibitor to a potent drug bioconjugate when delivered by gold nanoparticles. Bioconjug Chem 2014,25(2),207-215","journal-title":"Bioconjug Chem"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/j.1365-2184.2011.00787.x","volume":"44","author":"Xiao D.Z.","year":"2011","unstructured":"Xiao D.Z.; Dai B.; Chen J.; Luo Q.; Liu X.Y.; Lin Q.X.; Li X.H.; Huang W.; Yu X.Y.; Loss of macrophage migration inhibitory factor impairs the growth properties of human HeLa cervical cancer cells. Cell Prolif 2011,44(6),582-590","journal-title":"Cell Prolif"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1186\/1471-2407-14-630","volume":"14","author":"Oliveira C.S.","year":"2014","unstructured":"Oliveira C.S.; de Bock C.E.; Molloy T.J.; Sadeqzadeh E.; Geng X.Y.; Hersey P.; Zhang X.D.; Thorne R.F.; Macrophage migration inhibitory factor engages PI3K\/Akt signalling and is a prognostic factor in metastatic melanoma. BMC Cancer 2014,14(1),630","journal-title":"BMC Cancer"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jconrel.2011.06.004","volume":"155","author":"Huang H.C.","year":"2011","unstructured":"Huang H.C.; Barua S.; Sharma G.; Dey S.K.; Rege K.; Inorganic nanoparticles for cancer imaging and therapy. J Control Release 2011,155(3),344-357","journal-title":"J Control Release"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jsps.2017.10.012","volume":"26","author":"Rizvi S.A.A.","year":"2018","unstructured":"Rizvi S.A.A.; Saleh A.M.; Applications of nanoparticle systems in drug delivery technology. Saudi Pharm J 2018,26(1),64-70","journal-title":"Saudi Pharm J"},{"key":"ref=27","author":"Subramani K.","year":"2012","unstructured":"Subramani K.; Ahmed W.; Nanoparticulate. Drug Delivery Systems for Oral Cancer Treatment 2012","journal-title":"Drug Delivery Systems for Oral Cancer Treatment"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"407","DOI":"10.4103\/jomfp.JOMFP_29_17","volume":"21","author":"Poonia M.","year":"2017","unstructured":"Poonia M.; Ramalingam K.; Goyal S.; Sidhu S.K.; Nanotechnology in oral cancer: A comprehensive review. J Oral Maxillofac Pathol 2017,21(3),407-414","journal-title":"J Oral Maxillofac Pathol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.2147\/IJN.S61670","volume":"9","author":"Calixto G.","year":"2014","unstructured":"Calixto G.; Bernegossi J.; Fonseca-Santos B.; Chorilli M.; Nanotechnology-based drug delivery systems for treatment of oral cancer: A review. Int J Nanomedicine 2014,9,3719-3735","journal-title":"Int J Nanomedicine"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.addr.2012.09.033","volume":"64","author":"Brannon-Peppas L.","year":"2012","unstructured":"Brannon-Peppas L.; Blanchette J.O.; Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 2012,64,206-212","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"16071","DOI":"10.1038\/natrevmats.2016.71","volume":"1","author":"Li J.","year":"2016","unstructured":"Li J.; Mooney D.J.; Designing hydrogels for controlled drug delivery. Nat Rev Mater 2016,1(12),16071","journal-title":"Nat Rev Mater"},{"key":"ref=32","first-page":"25","author":"Maitra J.","year":"2014","unstructured":"Maitra J.; Kumar S.V.; Cross-linking in hydrogels-a review. Am J Polym Sci 2014,25-31","journal-title":"Am J Polym Sci"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/pi.5599","volume":"67","author":"Ketabat F.","year":"2018","unstructured":"Ketabat F.; Khorshidi S.; Karkhaneh A.; Application of minimally invasive injectable conductive hydrogels as stimulating scaffolds for myocardial tissue engineering. Polym Int 2018,67(8),975-982","journal-title":"Polym Int"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jconrel.2012.03.014","volume":"160","author":"Koutsopoulos S.","year":"2012","unstructured":"Koutsopoulos S.; Zhang S.; Two-layered injectable self-assembling peptide scaffold hydrogels for long-term sustained release of human antibodies. J Control Release 2012,160(3),451-458","journal-title":"J Control Release"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.tibtech.2017.06.015","volume":"35","author":"Sepantafar M.","year":"2017","unstructured":"Sepantafar M.; Maheronnaghsh R.; Mohammadi H.; Radmanesh F.; Hasani-Sadrabadi M.M.; Ebrahimi M.; Baharvand H.; Engineered hydrogels in cancer therapy and diagnosis. Trends Biotechnol 2017,35(11),1074-1087","journal-title":"Trends Biotechnol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1021\/acsbiomaterials.5b00346","volume":"1","author":"Qi X.","year":"2015","unstructured":"Qi X.; Wei W.; Li J.; Liu Y.; Hu X.; Zhang J.; Bi L.; Dong W.; Fabrication and characterization of a novel anticancer drug delivery system: Salecan\/poly (methacrylic acid) semi-interpenetrating polymer network hydrogel. ACS Biomater Sci Eng 2015,1(12),1287-1299","journal-title":"ACS Biomater Sci Eng"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0939-6411(03)00095-X","volume":"57","author":"Ruel-Gari&#xE9;py E.","year":"2004","unstructured":"Ruel-Gari&#xE9;py E.; Shive M.; Bichara A.; Berrada M.; Le Garrec D.; Chenite A.; Leroux J.C.; A thermosensitive chitosan-based hydrogel for the local delivery of paclitaxel. Eur J Pharm Biopharm 2004,57(1),53-63","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jconrel.2005.09.026","volume":"110","author":"Obara K.","year":"2005","unstructured":"Obara K.; Ishihara M.; Ozeki Y.; Ishizuka T.; Hayashi T.; Nakamura S.; Saito Y.; Yura H.; Matsui T.; Hattori H.; Takase B.; Ishihara M.; Kikuchi M.; Maehara T.; Controlled release of paclitaxel from photocrosslinked chitosan hydrogels and its subsequent effect on subcutaneous tumor growth in mice. J Control Release 2005,110(1),79-89","journal-title":"J Control Release"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S0168-3659(03)00364-X","volume":"92","author":"Konishi M.","year":"2003","unstructured":"Konishi M.; Tabata Y.; Kariya M.; Suzuki A.; Mandai M.; Nanbu K.; Takakura K.; Fujii S.; In vivo anti-tumor effect through the controlled release of cisplatin from biodegradable gelatin hydrogel. J Control Release 2003,92(3),301-313","journal-title":"J Control Release"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"6076","DOI":"10.1016\/j.biomaterials.2009.07.054","volume":"30","author":"Gurski L.A.","year":"2009","unstructured":"Gurski L.A.; Jha A.K.; Zhang C.; Jia X.; Farach-Carson M.C.; Hyaluronic acid-based hydrogels as 3D matrices for in vitro evaluation of chemotherapeutic drugs using poorly adherent prostate cancer cells. Biomaterials 2009,30(30),6076-6085","journal-title":"Biomaterials"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"516","DOI":"10.3109\/1061186X.2010.519031","volume":"19","author":"Gao Y.","year":"2011","unstructured":"Gao Y.; Ren F.; Ding B.; Sun N.; Liu X.; Ding X.; Gao S.; A thermo-sensitive PLGA-PEG-PLGA hydrogel for sustained release of docetaxel. J Drug Target 2011,19(7),516-527","journal-title":"J Drug Target"},{"key":"ref=42","first-page":"15","volume":"24","author":"Hao T.","year":"2009","unstructured":"Hao T.; Li Z.; Qiao M.; Fan Q.; Preparation of docetaxel hydrogels for subcutaneous injection and their release profile in vitro. Chung Kuo Yao Hsueh Tsa Chih 2009,24,15","journal-title":"Chung Kuo Yao Hsueh Tsa Chih"},{"key":"ref=43","first-page":"429","volume":"5","author":"Shaker D.S.","year":"2013","unstructured":"Shaker D.S.; Ghorab M.K.; Klingner A.; Teiama M.S.; In-situ injectable thermosensitive gel based on poloxamer as a new carrier for tamoxifen citrate. Int J Pharm Pharm Sci 2013,5(4),429-437","journal-title":"Int J Pharm Pharm Sci"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jconrel.2004.11.014","volume":"103","author":"Konishi M.","year":"2005","unstructured":"Konishi M.; Tabata Y.; Kariya M.; Hosseinkhani H.; Suzuki A.; Fukuhara K.; Mandai M.; Takakura K.; Fujii S.; In vivo anti-tumor effect of dual release of cisplatin and adriamycin from biodegradable gelatin hydrogel. J Control Release 2005,103(1),7-19","journal-title":"J Control Release"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/BF00688856","volume":"27","author":"Deurloo M.J.","year":"1991","unstructured":"Deurloo M.J.; Kop W.; van Tellingen O.; Bartelink H.; Begg A.C.; Intratumoural administration of cisplatin in slow-release devices: II. Pharmacokinetics and intratumoural distribution. Cancer Chemother Pharmacol 1991,27(5),347-353","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1021\/mp050028n","volume":"2","author":"Tauro J.R.","year":"2005","unstructured":"Tauro J.R.; Gemeinhart R.A.; Extracellular protease activation of chemotherapeutics from hydrogel matrices: A new paradigm for local chemotherapy. Mol Pharm 2005,2(5),435-438","journal-title":"Mol Pharm"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"e33860","DOI":"10.1371\/journal.pone.0033860","volume":"7","author":"Li J.","year":"2012","unstructured":"Li J.; Gong C.; Feng X.; Zhou X.; Xu X.; Xie L.; Wang R.; Zhang D.; Wang H.; Deng P.; Zhou M.; Ji N.; Zhou Y.; Wang Y.; Wang Z.; Liao G.; Geng N.; Chu L.; Qian Z.; Wang Z.; Chen Q.; Biodegradable thermosensitive hydrogel for SAHA and DDP delivery: Therapeutic effects on oral squamous cell carcinoma xenografts. PLoS One 2012,7(4),e33860","journal-title":"PLoS One"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"775","DOI":"10.5732\/cjc.010.10075","volume":"29","author":"Tang M.F.","year":"2010","unstructured":"Tang M.F.; Lei L.; Guo S.R.; Huang W.L.; Recent progress in nanotechnology for cancer therapy. Chin J Cancer 2010,29(9),775-780","journal-title":"Chin J Cancer"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15226\/2374-6866\/1\/1\/00109","volume":"1","author":"Pillai G.","year":"2014","unstructured":"Pillai G.; Nanomedicines for cancer therapy: An update of FDA approved and those under various stages of development. SOJ Pharm Pharm Sci 2014,1(2),1-13","journal-title":"SOJ Pharm Pharm Sci"},{"key":"ref=50","first-page":"159","volume":"3","author":"Jain N.","year":"2010","unstructured":"Jain N.; Jain R.; Thakur N.; Gupta B.R.; Nanotechnology: A safe and effective drug delivery system. AJPC 2010,3,159-165","journal-title":"AJPC"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.3390\/ph6111361","volume":"6","author":"D&#xED;az M.R.","year":"2013","unstructured":"D&#xED;az M.R.; Vivas-Mejia P.E.; Nanoparticles as drug delivery systems in cancer medicine: Emphasis on RNAi-containing nanoliposomes. Pharmaceuticals (Basel) 2013,6(11),1361-1380","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=52","first-page":"1","volume":"656","author":"Shi S.","year":"2020","unstructured":"Shi S.; Kang P.; Systemic review of biodegradable nanomaterials in nanomedicine. Nanomaterials (Basel) 2020,656(10),1-21","journal-title":"Nanomaterials (Basel)"},{"key":"ref=53","first-page":"17","volume":"1","author":"Sudhakara R.R.","year":"2015","unstructured":"Sudhakara R.R.; Sahithi D.; Nano drug delivery in oral cancer therapy: An emerging avenue to unveil. J Med Radiol Pathol Surg 2015,1,17-22","journal-title":"J Med Radiol Pathol Surg"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1016\/j.addr.2013.09.019","volume":"65","author":"Markman J.L.","year":"2013","unstructured":"Markman J.L.; Rekechenetskiy A.; Holler E.; Ljubimova J.Y.; Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv Drug Deliv Rev 2013,65(13-14),1866-1879","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"323","DOI":"10.4155\/tde.10.13","volume":"1","author":"Hu C.M.","year":"2010","unstructured":"Hu C.M.; Aryal S.; Zhang L.; Nanoparticle-assisted combination therapies for effective cancer treatment. Ther Deliv 2010,1(2),323-334","journal-title":"Ther Deliv"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/02652040802312572","volume":"26","author":"Tekade R.K.","year":"2009","unstructured":"Tekade R.K.; Dutta T.; Gajbhiye V.; Jain N.K.; Exploring dendrimer towards dual drug delivery: pH responsive simultaneous drug-release kinetics. J Microencapsul 2009,26(4),287-296","journal-title":"J Microencapsul"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.jconrel.2011.06.001","volume":"153","author":"Bae Y.H.","year":"2011","unstructured":"Bae Y.H.; Park K.; Targeted drug delivery to tumors: Myths, reality and possibility. J Control Release 2011,153(3),198-205","journal-title":"J Control Release"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1590\/S1984-82502013000400002","volume":"49","author":"Kushwaha S.K.","year":"2013","unstructured":"Kushwaha S.K.; Ghoshal S.; Rai A.K.; Singh S.; Carbon nanotubes as a novel drug delivery system for anticancer therapy: A review. Braz J Pharm Sci 2013,49(4),621-643","journal-title":"Braz J Pharm Sci"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/10717540490433895","volume":"11","author":"Paciotti G.F.","year":"2004","unstructured":"Paciotti G.F.; Myer L.; Weinreich D.; Colloidal gold: A novel nanoparticle vector for tumour directed drug delivery. Drug Deliv 2004,11(3),169-183","journal-title":"Drug Deliv"},{"key":"ref=60","first-page":"2","volume":"4","author":"Barakat N.S.","year":"2012","unstructured":"Barakat N.S.; Taleb D.A.; Salehitekade A.S.; Target nanoparticles: An appealing drug delivery platform. J Nanomed Nanotechnol 2012,4,2-9","journal-title":"J Nanomed Nanotechnol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.4314\/tjpr.v13i7.23","volume":"13","author":"Khan K.A.","year":"2014","unstructured":"Khan K.A.; Rashid R.; Murtaza G.; Zahra A.; Gold nanoparticles: Synthesis and applications in drug delivery. Trop J Pharm Res 2014,13(7),1169-1177","journal-title":"Trop J Pharm Res"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jconrel.2015.07.030","volume":"219","author":"Batrakova E.V.","year":"2015","unstructured":"Batrakova E.V.; Kim M.S.; Using exosomes, naturally-equipped nanocarriers, for drug delivery. J Control Release 2015,219,396-405","journal-title":"J Control Release"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ijpharm.2017.02.038","volume":"521","author":"Jiang X.C.","year":"2017","unstructured":"Jiang X.C.; Gao J.Q.; Exosomes as novel bio-carriers for gene and drug delivery. Int J Pharm 2017,521(1-2),167-175","journal-title":"Int J Pharm"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/j.jprot.2010.06.006","volume":"73","author":"Mathivanan S.","year":"2010","unstructured":"Mathivanan S.; Ji H.; Simpson R.J.; Exosomes: Extracellular organelles important in intercellular communication. J Proteomics 2010,73(10),1907-1920","journal-title":"J Proteomics"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1038\/mt.2010.105","volume":"18","author":"Sun D.","year":"2010","unstructured":"Sun D.; Zhuang X.; Xiang X.; Liu Y.; Zhang S.; Liu C.; Barnes S.; Grizzle W.; Miller D.; Zhang H.G.; A novel nanoparticle drug delivery system: The anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol Ther 2010,18(9),1606-1614","journal-title":"Mol Ther"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1016\/j.biomaterials.2013.11.083","volume":"35","author":"Tian Y.","year":"2014","unstructured":"Tian Y.; Li S.; Song J.; Ji T.; Zhu M.; Anderson G.J.; Wei J.; Nie G.; A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials 2014,35(7),2383-2390","journal-title":"Biomaterials"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.apsb.2016.02.001","volume":"6","author":"Ha D.","year":"2016","unstructured":"Ha D.; Yang N.; Nadithe V.; Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: Current perspectives and future challenges. Acta Pharm Sin B 2016,6(4),287-296","journal-title":"Acta Pharm Sin B"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/aps.2017.12","volume":"38","author":"Luan X.","year":"2017","unstructured":"Luan X.; Sansanaphongpricha K.; Myers I.; Chen H.; Yuan H.; Sun D.; Engineering exosomes as refined biological nanoplatforms for drug delivery. Acta Pharmacol Sin 2017,38(6),754-763","journal-title":"Acta Pharmacol Sin"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/jbm.b.33943","volume":"106","author":"Desai K.G.H.","year":"2018","unstructured":"Desai K.G.H.; Polymeric drug delivery systems for intraoral site-specific chemoprevention of oral cancer. J Biomed Mater Res B Appl Biomater 2018,106(3),1383-1413","journal-title":"J Biomed Mater Res B Appl Biomater"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1021\/acs.molpharmaceut.5b00461","volume":"12","author":"Satapathy S.R.","year":"2015","unstructured":"Satapathy S.R.; Siddharth S.; Das D.; Nayak A.; Kundu C.N.; Enhancement of cytotoxicity and inhibition of angiogenesis in oral cancer stem cells by a hybrid nanoparticle of bioactive quinacrine and silver: Implication of base excision repair cascade. Mol Pharm 2015,12(11),4011-4025","journal-title":"Mol Pharm"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"111","DOI":"10.5505\/ejm.2019.66487","volume":"24","author":"Yesilot S.","year":"2019","unstructured":"Yesilot S.; Aydin C.; Silver nanoparticles; a new hope in cancer therapy. East J Med 2019,24(1),111-116","journal-title":"East J Med"},{"key":"ref=72","first-page":"117","volume":"17","author":"Rana V.","year":"2016","unstructured":"Rana V.; Therapeutic delivery. Ther Deliv 2016,17,117-138","journal-title":"Ther Deliv"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.oraloncology.2012.09.015","volume":"49","author":"Zlotogorski A.","year":"2013","unstructured":"Zlotogorski A.; Dayan A.; Dayan D.; Chaushu G.; Salo T.; Vered M.; Nutraceuticals as new treatment approaches for oral cancer-I: Curcumin Oral Oncol 2013,49(3),187-191","journal-title":"Curcumin Oral Oncol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.colsurfb.2011.02.038","volume":"85","author":"Liu D.","year":"2011","unstructured":"Liu D.; Liu Z.; Wang L.; Zhang C.; Zhang N.; Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf B Biointerfaces 2011,85(2),262-269","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=75","first-page":"321","volume":"27","author":"Iida S.","year":"2013","unstructured":"Iida S.; Shimada J.; Sakagami H.; Cytotoxicity induced by docetaxel in human oral squamous cell carcinoma cell lines. In vivo 2013,27,321-332","journal-title":"In vivo"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ejps.2011.04.005","volume":"43","author":"Zhang T.","year":"2011","unstructured":"Zhang T.; Chen J.; Zhang Y.; Shen Q.; Pan W.; Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide. Eur J Pharm Sci 2011,43(3),174-179","journal-title":"Eur J Pharm Sci"},{"key":"ref=77","first-page":"542","volume":"4","author":"Kushwaha K.S","year":"2012","unstructured":"Kushwaha K.S; Rastogi A; Rai A.K; Singh S.; Novel drug delivery system for anti-cancer- a review. Int J Pharm Tech Res 2012,4,542-553","journal-title":"Int J Pharm Tech Res"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/417329a","volume":"417","author":"Panda S.","year":"2002","unstructured":"Panda S.; Hogenesch J.B.; Kay S.A.; Circadian rhythms from flies to human. Nature 2002,417(6886),329-335","journal-title":"Nature"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.tcb.2013.07.002","volume":"24","author":"Partch C.L.","year":"2014","unstructured":"Partch C.L.; Green C.B.; Takahashi J.S.; Molecular architecture of the mammalian circadian clock. Trends Cell Biol 2014,24(2),90-99","journal-title":"Trends Cell Biol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1126\/science.1086271","volume":"302","author":"Matsuo T.","year":"2003","unstructured":"Matsuo T.; Yamaguchi S.; Mitsui S.; Emi A.; Shimoda F.; Okamura H.; Control mechanism of the circadian clock for timing of cell division in vivo. Science 2003,302,255-259","journal-title":"Science"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"16219","DOI":"10.1073\/pnas.1408886111","volume":"111","author":"Zhang R.","year":"2014","unstructured":"Zhang R.; Lahens N.F.; Ballance H.I.; Hughes M.E.; Hogenesch J.B.; A circadian gene expression atlas in mammals: Implications for biology and medicine. Proc Natl Acad Sci USA 2014,111(45),16219-16224","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1523\/JNEUROSCI.3222-16.2017","volume":"37","author":"Akle V.","year":"2017","unstructured":"Akle V.; Stankiewicz A.J.; Kharchenko V.; Yu L.; Kharchenko P.V.; Zhdanova I.V.; Circadian kinetics of cell cycle progression in adult neurogenic niches of a diurnal vertebrate. J Neurosci 2017,37(7),1900-1909","journal-title":"J Neurosci"},{"key":"ref=83","first-page":"6","author":"Lamia K.","year":"2017","unstructured":"Lamia K.; Ticking time bombs: Connections between circadian clocks and cancer. F1000. Fac Rev 2017,6","journal-title":"Fac Rev"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.cmet.2016.07.001","volume":"24","author":"Papagiannakopoulos T.","year":"2016","unstructured":"Papagiannakopoulos T.; Bauer M.R.; Davidson S.M.; Heimann M.; Subbaraj L.; Bhutkar A.; Bartlebaugh J.; Vander Heiden M.G.; Jacks T.; Circadian rhythm disruption promotes lung tumorigenesis. Cell Metab 2016,24(2),324-331","journal-title":"Cell Metab"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.cels.2018.01.013","volume":"6","author":"Ye Y.","year":"2018","unstructured":"Ye Y.; Xiang Y.; Ozguc F.M.; Kim Y.; Liu C.J.; Park P.K.; Hu Q.; Diao L.; Lou Y.; Lin C.; Guo A.Y.; Zhou B.; Wang L.; Chen Z.; Takahashi J.S.; Mills G.B.; Yoo S.H.; Han L.; The genomic landscape and pharmacogenomic interactions of clock genes in cancer chronotherapy. Cell Syst 2018,6(3),314-328.e2","journal-title":"Cell Syst"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1124\/pr.116.013441","volume":"69","author":"Ballesta A.","year":"2017","unstructured":"Ballesta A.; Innominato P.F.; Dallmann R.; Rand D.A.; L&#xE9;vi F.A.; Systems chronotherapeutics. Pharmacol Rev 2017,69(2),161-199","journal-title":"Pharmacol Rev"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1146\/annurev.pharmtox.48.113006.094626","volume":"50","author":"L&#xE9;vi F.","year":"2010","unstructured":"L&#xE9;vi F.; Okyar A.; Dulong S.; Innominato P.F.; Clairambault J.; Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol 2010,50(1),377-421","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1146\/annurev.pharmtox.47.120505.105208","volume":"47","author":"Levi F.","year":"2007","unstructured":"Levi F.; Schibler U.; Circadian rhythms: Mechanisms and therapeutic implications. Annu Rev Pharmacol Toxicol 2007,47(1),593-628","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/cncr.11040","volume":"97","author":"Mormont M.C.","year":"2003","unstructured":"Mormont M.C.; Levi F.; Cancer chronotherapy: Principles, applications, and perspectives. Cancer 2003,97(1),155-169","journal-title":"Cancer"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ejps.2008.10.024","volume":"36","author":"Altinok A.","year":"2009","unstructured":"Altinok A.; L&#xE9;vi F.; Goldbeter A.; Identifying mechanisms of chronotolerance and chronoefficacy for the anticancer drugs 5-fluorouracil and oxaliplatin by computational modeling. Eur J Pharm Sci 2009,36(1),20-38","journal-title":"Eur J Pharm Sci"},{"key":"ref=91","first-page":"299","author":"L&#xE9;vi F.","year":"1997","unstructured":"L&#xE9;vi F.; Redfern P.; Lemmer B.; Chronopharmacology of anticancer agents. Physiology and Pharmacology of Biological Rhythms 1997,299-233","journal-title":"Physiology and Pharmacology of Biological Rhythms"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.cell.2006.03.033","volume":"125","author":"Doi M.","year":"2006","unstructured":"Doi M.; Hirayama J.; Sassone-Corsi P.; Circadian regulator CLOCK is a histone acetyltransferase. Cell 2006,125(3),497-508","journal-title":"Cell"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0092-8674(00)81014-4","volume":"98","author":"Kume K.","year":"1999","unstructured":"Kume K.; Zylka M.J.; Sriram S.; Shearman L.P.; Weaver D.R.; Jin X.; Maywood E.S.; Hastings M.H.; Reppert S.M.; mCRY1 and mCRY2 are essential components of the negative limb of the circadian clock feedback loop. Cell 1999,98(2),193-205","journal-title":"Cell"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/ng1745","volume":"38","author":"Sato T.K.","year":"2006","unstructured":"Sato T.K.; Yamada R.G.; Ukai H.; Baggs J.E.; Miraglia L.J.; Kobayashi T.J.; Welsh D.K.; Kay S.A.; Ueda H.R.; Hogenesch J.B.; Feedback repression is required for mammalian circadian clock function. Nat Genet 2006,38(3),312-319","journal-title":"Nat Genet"},{"key":"ref=95","doi-asserted-by":"crossref","first-page":"110566","DOI":"10.1016\/j.colsurfb.2019.110566","volume":"185","author":"Chaiyakarn P.","year":"2020","unstructured":"Chaiyakarn P.; Theerasak R.; Opanasopit P.; Ngawhirunpat T.; Patrojanasophon P.; Synthesis of novel N-vinylpyrrolidone\/acrylic acid nanoparticles as drug delivery carriers of cisplatin to cancer cells. Colloids Surf B Biointerfaces 2020,185,110566","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=96","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.3390\/cancers11081108","volume":"11","author":"Xin H.K.","year":"2019","unstructured":"Xin H.K.; Ian C.; Bey-Hing G.; Cisplatin-resistance in oral squamous cell carcinoma: Regulation by tumour cell-derived extracellular vesicles. Cancers (Basel) 2019,11(18),1108-1166","journal-title":"Cancers (Basel)"},{"key":"ref=97","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1002\/jps.22514","volume":"100","author":"Haifeng Z.","year":"2011","unstructured":"Haifeng Z.; Yang G.; Wei V.; Preparation of bleomycin A2\u2013PLGA microspheres and related in vitro and in vivo studies. J Pharm Sci 2011,100(7),2790-2800","journal-title":"J Pharm Sci"},{"key":"ref=98","first-page":"10705","volume":"15","author":"Mehran M.","year":"2011","unstructured":"Mehran M.; Rana Jahanban E.; Monfaredan A.; Oral and IV dosages of doxorubicin-methotrexate loaded nanoparticles inhibit progression of oral cancer by downregulation of matrix methaloproteinase expression in vivo. Asian Pac J Cancer Prev 2011,15(24),10705-10711","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref=99","first-page":"2541","volume":"15","author":"Jin B.Z.","year":"2018","unstructured":"Jin B.Z.; Dong X.Q.; Xu X.; Zhang F.H.; Development and in vitro evaluation of mucoadhesive patches of methotrexate for targeted delivery in oral cancer. Oncol Lett 2018,15(2),2541-2549","journal-title":"Oncol Lett"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2217\/nnm-2019-0415","volume":"15","author":"Liu Z.","year":"2020","unstructured":"Liu Z.; Shi J.; Zhu B.; Xu Q.; Development of a multifunctional gold nanoplatform for combined chemo-photothermal therapy against oral cancer. Nanomedicine (Lond) 2020,15(7),661-676","journal-title":"Nanomedicine (Lond)"},{"key":"ref=101","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/sj.cgt.7700529","volume":"10","author":"Dehari H.","year":"2003","unstructured":"Dehari H.; Ito Y.; Enhanced antitumour effect of RGD fiber-modified adenovirus for gene therapy of oral cancer. Cancer Gene Ther 2003,10,75","journal-title":"Cancer Gene Ther"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1001\/archotol.128.8.880","volume":"128","author":"Wenig B.L.","year":"2002","unstructured":"Wenig B.L.; Werner J.A.; Castro D.J.; Sridhar K.S.; Garewal H.S.; Kehrl W.; Pluzanska A.; Arndt O.; Costantino P.D.; Mills G.M.; Dunphy F.R.; Orenberg E.K.; Leavitt R.D.; The role of intratumoral therapy with cisplatin\/epinephrine injectable gel in the management of advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2002,128(8),880-885","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.colsurfb.2013.03.039","volume":"110","author":"Arulmozhi V.","year":"2013","unstructured":"Arulmozhi V.; Pandian K.; Mirunalini S.; Ellagic acid encapsulated chitosan nanoparticles for drug delivery system in human oral cancer cell line (KB). Colloids Surf B Biointerfaces 2013,110,313-320","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3322\/caac.20114","volume":"61","author":"Agostinis P.","year":"2011","unstructured":"Agostinis P.; Berg K.; Cengel K.A.; Foster T.H.; Girotti A.W.; Gollnick S.O.; Hahn S.M.; Hamblin M.R.; Juzeniene A.; Kessel D.; Korbelik M.; Moan J.; Mroz P.; Nowis D.; Piette J.; Wilson B.C.; Golab J.; Photodynamic therapy of cancer: An update. CA Cancer J Clin 2011,61(4),250-281","journal-title":"CA Cancer J Clin"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1002\/smll.201601094","volume":"12","author":"Guo R.","year":"2016","unstructured":"Guo R.; Peng H.; Tian Y.; Shen S.; Yang W.; Mitochondria-targeting magnetic composite nanoparticles for enhanced phototherapy of cancer. Small 2016,12(33),4541-4552","journal-title":"Small"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s10103-007-0470-x","volume":"23","author":"Huang X.","year":"2008","unstructured":"Huang X.; Jain P.K.; El-Sayed I.H.; El-Sayed M.A.; Plasmonic photothermal therapy (PPTT) using gold nanoparticles. Lasers Med Sci 2008,23(3),217-228","journal-title":"Lasers Med Sci"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/prd.12388","volume":"87","author":"Radaic A.","year":"2021","unstructured":"Radaic A.; Ganther S.; Kamarajan P.; Grandis J.; Yom S.S.; Kapila Y.L.; Paradigm shift in the pathogenesis and treatment of oral cancer and other cancers focused on the oralome and antimicrobial-based therapeutics. Periodontol 2000 2021,87(1),76-93","journal-title":"Periodontol 2000"},{"key":"ref=108","doi-asserted-by":"crossref","first-page":"103458","DOI":"10.1016\/j.critrevonc.2021.103458","author":"Grigolato R.","year":"2021","unstructured":"Grigolato R.; Oral cancer in non-smoker non-drinker patients. Could comparative pet oncology help to understand risk factors and pathogenesis? Crit Rev Oncol Hematol 2021,103458","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"9977131","DOI":"10.1155\/2021\/9977131","volume":"2021","author":"Zheng W.","year":"2021","unstructured":"Zheng W.; Zhou Q.; Yuan C.; Nanoparticles for oral cancer diagnosis and therapy. Bioinorg Chem Appl 2021,2021,9977131","journal-title":"Bioinorg Chem Appl"}],"container-title":["Current Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1567201819666220408094520","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/203274\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1567201819666220408094520","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T02:43:55Z","timestamp":1676515435000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/203274\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":109,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1567201819666220408094520","relation":{},"ISSN":["1567-2018"],"issn-type":[{"value":"1567-2018","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-09-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}